Board summary
Key figures
39,531
Registered population
57.8% aged 18–64
21.7%
Aged 65+
ICB 19.9% · England 17.9%
14.2%
Ethnic minority (non-White)
6.0% Asian · England 9.6%
2.5%
In IMD quintile 1
ICB 17.1% · England 21.0%
~1,078
Core20 residents (est.)
Resident basis; registered basis ~1,028 · see page 3
7,466
Hypertension register
+6.36% in 3 yrs · England +5.60%
350
SMI register
12.3% of Medway (LAD)'s
823
COPD register
Reviews -11.49% in 3 yrs
Forecast to 2030
9,221
Hypertension patients, 2030
+1,755 on today
71.5%
QRISK ≥20% on statins, 2030
+2.36pp over 3 yrs
5.9%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England and fell sharply.
Only 52.2% of asthma patients had a review (England 65.7%), a -10.7% three-year change leaving an estimated 1,194 register scale gap.
SMI blood pressure checks and hypertension control lag.
SMI blood pressure checks reached 73.6% (England 83.4%, three-year change -6.3 pp), while hypertension treatment to target sits at 64.5% (England 70.3%).
Lipid therapy and statin prescribing exceed national averages.
Lipid-lowering therapy for QRISK ≥ 20% reaches 66.5% (England 63.6%), and statin treatment in diabetes without CVD reaches 75.8% (England 73.2%).
Population, age and ethnicity
Patients aged 65+ account for 21.7% of the list, above Medway and England
Across 39,531 registered patients, 21.7% (8,591) are aged 65+, higher than Medway (17.9%), the ICB (19.9%) and England (17.9%). The 18–64 group comprises 57.8% (Medway 60.4%, ICB 59.5%, England 62.7%), while under-18s represent 20.4% (Medway 21.6%, ICB 20.7%, England 19.6%). Census resident estimates show 85.8% White ethnicity (Medway 84.3%, ICB 88.6%, England 81.1%) and 14.2% ethnic minorities, though resident Census profiles differ from GP registrations. List growth is projected at 9.1% to 2030 (Medway 7.0%, ICB 6.0%, England 2.3%), under an unverified methodology.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Medway (LAD) local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Medway LA) | 1,507 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 84.2% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Medway LA) | 740 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Medway LA) | 19.5 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 2.5% overall and concentrated entirely within Thorndike Partnership
Core20 deprivation is 2.5%, below Medway LAD (23.1%), NHS Kent and Medway ICB (17.1%) and England (21.0%). Deprivation concentrates in Thorndike Partnership (8.6% share, estimated 1,028 patients); The Elms Medical Centre and Highparks Medical Practice record 0.0% (0.12 pp reconciliation difference versus 1,078 resident estimate). Across 350 severe mental illness patients network-wide, blood pressure checks fell 6.3 pp to 73.6% (England +4.4 pp) and BMI checks fell 6.8 pp to 68.5% (England +5.1 pp). Core20 deprivation is concentrated at Thorndike Partnership, while network-wide SMI physical checks lag national trends.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
350
SMI register
0.87% recorded prevalence
201
Learning disability register
0.50% recorded prevalence
21
Care homes, 549 beds
In the PCN catchment
8.9%
Provide unpaid care
Medway (LAD), Census 2021
Learning disability prevalence is 0.5% (201 patients; Medway 0.7%, ICB 0.6%, England 0.6%) and severe mental illness is 0.9% (350 patients; Medway 0.9%, ICB 0.9%, England 1.0%). Catchment care homes total 21 (549 beds), with dementia prevalence at 1.0% (401 patients, up +17.4% over three years; Medway 0.6%, ICB 0.8%, England 0.8%).
Severe mental illness: physical health checks
SMI blood pressure checks fell 6.3 pp to 73.6% (England 83.4%, +4.4 pp), with The Elms Medical Centre at 58.6% and Highparks Medical Practice at 67.4%. BMI checks fell 6.8 pp to 68.5% (England 82.1%, +5.1 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,466
Hypertension register
+6.36%
Register growth, 3 yrs
Medway (LAD) +3.74% · England +5.60%
−3.30pp
BP control, under 80
≤140/90 · −1.36pp aged 80+
+1,755
More patients by 2030
Forecast 9,221 (21.03%)
Hypertension case-finding and control
Hypertension register prevalence is 18.6% (7,466 patients), exceeding England (15.2%), Medway (15.4%), and the ICB (16.2%), though crude rates are not age-adjusted. Blood pressure checks reached 87.0% (+2.6 pp over three years; England +3.1 pp). However, patients treated to target fell 3.3 pp to 64.5%, below England (70.3%, +2.5 pp). Control in patients aged under 80 fell 3.3 pp to 61.6% (England 67.8%, +2.1 pp), with The Elms Medical Centre at 58.8% and Highparks Medical Practice at 59.2%.
Lipids and statins
For patients with QRISK at or above 20%, lipid-lowering therapy uptake is 66.5%, exceeding England (63.6%), Medway (64.0%), and the ICB (61.4%). Statin coverage in diabetes without CVD also leads comparators at 75.8% (England 73.2%).
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 102,068 | £1.40 | £1.90 | £1.86 | £142,895 |
| Cardiovascular (all), 2025 | 110,441 | £2.42 | £3.57 | £3.33 | £267,267 |
For lipid-regulating drugs in 2026, the PCN prescribed 102,068 items at £1.40 per item, compared to £1.86 in England, £1.87 in Medway, and £1.90 across the ICB. Prescribing spend was £46,951 less than at England's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−10.72%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.08%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.6%, matching England (6.6%), but annual reviews fell 6.3 pp over three years (England +2.8 pp) to 52.2% (England 65.7%), indicating an unreviewed scale gap of 1,194 patients across the 2,496 register. Meanwhile, youth asthma prescribing reached 1,551 items per 1,000 aged 5–19, above England (1,488). Similarly, COPD reviews dropped 11.5% over three years (England +2.8%) to 69.9% (England 76.4%) across 823 patients.
Cancer register and children's immunisation
Cancer prevalence is 4.7% (England 3.8%) across 1,905 patients. For childhood immunisations, age-5 MMR dose 1 reaches 97.1% (England 91.7%), exceeding the 95.0% target. However, dose 2 achieves 84.5% (England 82.8%), sitting 10.5 pp below the 95.0% target—a 12.6 pp dose contrast across the PCN cohort, widening to 24 pp at Thorndike Partnership.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
Across NHS Kent and Medway ICB in 2022, 55.6% of cancers with a known stage (4,661 of 8,384) were diagnosed at stage 1 or 2 (England 55.3%). Known stage was recorded for 63.6% of registered ICB cancers (8,384 of 13,189; England 67.0%). Reaching the 75.0% national ambition requires 1,627 additional early-stage diagnoses annually across the ICB, where early-stage share rose 2.2 pp since 2013. PCN cervical screening coverage is 73.7% (England 66.8%), with The Elms Medical Centre at 70.9%. Three-year change was -1.6% (England -1.0%), with Highparks Medical Practice at -2.7%. Reversing screening declines supports early detection across the network.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At acute provider level for July 2026 (provisional), Medway NHS Foundation Trust achieved 81.6% against the 85.0% 62-day cancer standard, exceeding NHS Kent and Medway Integrated Care Board (75.9%) and England (71.2%), while Maidstone and Tunbridge Wells NHS Trust reached 87.4%. Medway NHS Foundation Trust met the 75.0% faster diagnosis standard at 77.8% (ICB 76.8%, England 79.3%) and reached 99.6% on the 96.0% 31-day standard. For diagnostic waits, 14.2% waited 6+ weeks across all diagnostic tests (England 23.1%), with sleep studies at 90.4% and cardiology echocardiography at 36.6%.
| Pathways within standard (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 77.77 | 81.78 | 67.45 | 76.78 | 79.32 |
| 31-day treatment (96%) | 99.62 | 98.35 | 81.88 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 81.64 | 87.43 | 50.25 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Medway | Maidstone and Tunbridge Wells | Mid and South Essex | England |
|---|---|---|---|---|
| MRI | 0.68 | 0.92 | 23.35 | 21.40 |
| CT | 0.00 | 0.51 | 6.07 | 9.92 |
| Echocardiography | 36.62 | 2.57 | 65.05 | 28.48 |
| Colonoscopy | 1.88 | 19.80 | 64.09 | 30.83 |
| Gastroscopy | 3.32 | 24.03 | 59.76 | 29.02 |
| All 15 DM01 tests | 14.20 | 6.42 | 41.54 | 23.14 |
| Community services activity | Medway residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 43,510 | 254,055 |
| Referrals | 8,580 | 68,085 |
| Patients with a contact | 11,540 | 72,060 |
Community services (residents of Medway), Jun 2026 (provisional). At local authority level in June 2026 (provisional experimental data), Medway residents recorded 31,250 community care activities and 43,510 community care contacts, within an ICB total of 297,595 activities. Adults aged 65+ accounted for 62% of Medway residents' community contacts (26,985 of 43,510), describing wider borough community caseload.
Practice variation and patient experience
Practice variation and patient experience
In 2025/26, overall QOF achievement reached 95.5% at Highparks Medical Practice, 93.6% at Thorndike Partnership, and 88.5% at The Elms Medical Centre (England 92.5%). In the vaccination and immunisation domain, Highparks Medical Practice achieved 61.4% and Thorndike Partnership reached 45.8% (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Elms | 98 | 0.0 | 23.3% | 62.6% | 69.2% |
| Highparks Medical | 93 | 0.0 | 17.1% | 62.3% | 54.0% |
| Thorndike | 99 | 8.6 | 34.6% | 53.1% | 42.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Nineteen of 25 measures trail England trends, led by declining chronic disease reviews
Across 25 compared measures, 19 trail England's three-year trend. The widest relative lags appear in routine annual reviews: heart failure reviews fell 9.4% (England +8.7%, trailing by 18.1 points), asthma reviews fell 10.7% (England +4.4%, trailing by 15.16 points), and COPD reviews fell 11.5% (England +2.8%, trailing by 14.24 points). Severe mental illness checks also dropped, including BMI checks which fell 6.8 pp (England +5.1 pp, trailing by 11.88 pp). In contrast, breast screening rose +11.8% (England +8.4%), while dementia (+17.4%) and learning disability (+15.6%) registers expanded faster than England (+6.0% and +5.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Asthma reviews
COPD reviews
BMI record (SMI)
BP check (SMI)
Breast screening (53-70)
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Medway (LAD) | Asset | PCN | Medway (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (549 beds) | n/a | Schools (catchment) | 64 | n/a |
| Children's centres | 4 | 19 | Places of worship | 39 | 110 |
| Libraries | 3 | 9 | Food banks (VCS) | 1 | 6 |
| Homelessness support (VCS) | n/a | 9 | Day centres (VCS) | 3 | 29 |
| Children and young people (VCS) | 12 | 65 | Carers support groups (VCS) | 12 | 22 |
| Primary schools (LA maintained) | 6 | 17 | Primary academies | 14 | 56 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma review recall
Asthma review coverage is 52.2% (falling 6.3 pp; England 65.7%, +2.8 pp), indicating a scale gap of 1,194 unreviewed patients across the 2,496 register. For discussion, practices could run structured annual review recalls using shared templates and flexible slots, prioritising Thorndike Partnership (8.6% Core20 share, 1,028 estimated patients). Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Combined SMI physical health checks
Across 350 SMI patients, annual BP checks reached 73.6% (9.8 pp below England's 83.4%, falling 6.3 pp) and BMI checks 68.5% (13.6 pp below England's 82.1%). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Pharmacist-led hypertension titration reviews
Across 7,466 hypertension patients (18.6% prevalence), treatment to target is 64.5% (5.8 pp below England's 70.3%, falling 3.3 pp) and under-80 control is 61.6% (England 67.8%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult capacity planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | — | Practice |
| Option 1 · Structured asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
| Option 2 · Combined SMI physical health checks (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN & Practice |
| Option 3 · Pharmacist-led hypertension titration reviews (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
